WOS: 000264891700020PubMed ID: 18452496SRL is a new and potent immunosuppressive agent that has been successfully introduced in organ transplantation. In contrast to other immunosuppressive agents, SRL has a potent antitumor activity both in vitro and in vivo. Herein, we report a child with Kaposi's sarcoma that was diagnosed 30 months after LDLT and treated successfully with only conversion to SRL monotherapy. KS regressed completely at the end of the first month and remained in remission during 28 months follow-up
We present a case report of a patient with diffuse skin and systemic Kaposi's sarcoma (KS), 1 year a...
INTRODUCTION: Since 1999, a new immunosuppressive drug was administered to renal transplant patients...
Immunosuppressive treatment increases the risk of infection and malignancy in organ transplant recip...
Renal transplant recipients are susceptible to Kaposi's sarcoma (KS) because of treatment with immun...
<p>Kaposi᾽s sarcoma (KS) can develop in 0.06% to 4.1% of kidney transplant recipients. Here we descr...
[[abstract]]Sirolimus is one of the treatment modalities in organ transplant recipients with Kaposi’...
Background. Recipients of organ transplants are susceptible to Kaposi’s sarcoma as a result of treat...
background Recipients of organ transplants are susceptible to Kaposi’s sarcoma as a result of treat...
Development of KS in pediatric liver transplant recipients is a rare entity and has dismal prognosis...
WOS: 000230024800058PubMed ID: 15964375Kaposi's sarcoma has a higher incidence in organ transplant r...
CsA-free therapy, whereas 9.2 % of those receiving SRLCsA (P0.03) developed tumors. In conclusion, i...
[[abstract]]Sirolimus is one treatment option in transplant recipients with Kaposi's sarcoma (KS), w...
Sirolimus is one treatment option in transplant recipients with Kaposi's sarcoma (KS), which involve...
A case of a long-term management of a patient with Kaposi’s sarcoma developed as presumably related ...
A case of observation of a patient who developed Kaposi’s sarcoma after kidney transplantation is pr...
We present a case report of a patient with diffuse skin and systemic Kaposi's sarcoma (KS), 1 year a...
INTRODUCTION: Since 1999, a new immunosuppressive drug was administered to renal transplant patients...
Immunosuppressive treatment increases the risk of infection and malignancy in organ transplant recip...
Renal transplant recipients are susceptible to Kaposi's sarcoma (KS) because of treatment with immun...
<p>Kaposi᾽s sarcoma (KS) can develop in 0.06% to 4.1% of kidney transplant recipients. Here we descr...
[[abstract]]Sirolimus is one of the treatment modalities in organ transplant recipients with Kaposi’...
Background. Recipients of organ transplants are susceptible to Kaposi’s sarcoma as a result of treat...
background Recipients of organ transplants are susceptible to Kaposi’s sarcoma as a result of treat...
Development of KS in pediatric liver transplant recipients is a rare entity and has dismal prognosis...
WOS: 000230024800058PubMed ID: 15964375Kaposi's sarcoma has a higher incidence in organ transplant r...
CsA-free therapy, whereas 9.2 % of those receiving SRLCsA (P0.03) developed tumors. In conclusion, i...
[[abstract]]Sirolimus is one treatment option in transplant recipients with Kaposi's sarcoma (KS), w...
Sirolimus is one treatment option in transplant recipients with Kaposi's sarcoma (KS), which involve...
A case of a long-term management of a patient with Kaposi’s sarcoma developed as presumably related ...
A case of observation of a patient who developed Kaposi’s sarcoma after kidney transplantation is pr...
We present a case report of a patient with diffuse skin and systemic Kaposi's sarcoma (KS), 1 year a...
INTRODUCTION: Since 1999, a new immunosuppressive drug was administered to renal transplant patients...
Immunosuppressive treatment increases the risk of infection and malignancy in organ transplant recip...